一种估算1型糖尿病干预措施长期健康与成本结局的新模拟模型
研究基于DCCT/EDIC和EDC研究数据,开发了包含14种糖尿病相关并发症与死亡风险方程、12个危险因素进展方程及14种并发症效用方程的美国1型糖尿病微观模拟模型,内部验证平均绝对百分比误差为9%,外部验证结果不一,并以扩大胰岛素泵联合持续葡萄糖监测使用为例展示模型用途。
要点
- 模型整合14种并发症与死亡风险方程、12个危险因素进展方程及14种并发症效用方程。
- 内部验证平均绝对百分比误差为9%,累积失败率相关系数高于0.9。
- 外部验证结果不一,各并发症与研究间存在轻度低估或高估。
核心结论
- 该新的综合性1型糖尿病模拟模型可为评估美国1型糖尿病管理干预措施的长期成本效果生成有效且准确的结果。
研究设计与样本
- 基于DCCT/EDIC研究和EDC研究数据开发美国1型糖尿病微观模拟模型,包含14种糖尿病相关并发症与死亡的风险方程、12个危险因素进展方程及14种并发症的效用方程。
主要发现
- 模型可根据1型糖尿病并发症危险因素的变化生成长期临床与经济结局。
- 内部验证中,模型预测值与建模所用观察数据比较,所有并发症的平均绝对百分比误差为9%,累积失败率相关系数高于0.9。
- 外部验证结果不一,各并发症与研究间存在轻度低估或高估。
- 以扩大胰岛素泵联合持续葡萄糖监测至所有1型糖尿病患者为例的案例研究展示了模型的应用。
局限性
- 外部验证结果不一,各并发症与研究间存在轻度低估或高估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To develop a U.S.-based microsimulation model for assessing the cost-effectiveness of interventions to manage type 1 diabetes. RESEARCH DESIGN AND METHODS: We developed risk equations for 14 diabetes-related complications and mortality, 12 risk factor progression equations, and one equation for utilities associated with 14 complications using data from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) studies and the Epidemiology of Diabetes Complications (EDC) study. We integrated all equations into a simulation model. We conducted internal and external validation and demonstrated the utility of the model using a real-world example. Main model-generated outcomes included cumulative incidence of diabetes-related complications, life years, quality-adjusted life years, medical costs, and incremental cost-effectiveness ratios. RESULTS: The model generates long-term clinical and economic outcomes from changes in risk factors of type 1 diabetes complications. Internal validation comparing modeled outcomes to observed data used to develop the model yielded good prediction accuracy, with mean absolute percentage error across all complications of 9% and correlation of cumulative failure rates above 0.9. External validation results were mixed, with occurrence of slight under- or overprediction across complications and studies. We illustrated the model with a case study estimating the effects of expanding the use of an insulin pump with continuous glucose monitoring to all people with type 1 diabetes. CONCLUSIONS: Our new comprehensive type 1 diabetes simulation model can generate valid and accurate results for assessing the long-term cost-effectiveness of interventions to manage type 1 diabetes in the U.S.
引用
- Barbosa C, Hoerger TJ, Mack NA, et al. A New Simulation Model to Estimate the Long-term Health and Cost Outcomes of Interventions for People With Type 1 Diabetes. Diabetes Care. 2025. PMID: 40608287. doi:10.2337/dc25-0124
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。